- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07926490
Risk Factors for Postoperative Outcomes and Complications in Patients With Large Intrathoracic Tumors: A Multicenter Analysis
Risk Factors for Outcomes and Postoperative Complications in Patients with Large Intrathoracic Neoplasms (GIANTOR) What is the purpose of this study? The main goal of this study is to evaluate the results of surgery for removing very large tumors inside the chest. While common lung cancers are well-studied, other types of chest tumors (like solitary fibrous tumors or nerve-related tumors) can grow slowly and reach a massive size (over 5 cm) before they are found. Because these cases are rare, there is little data on the best way to operate on them. Researchers want to identify the risks and complications associated with these surgeries to improve patient care.
Why is this study important? Operating on large chest tumors is technically difficult because they often press against or grow into nearby vital organs. Currently, doctors mostly rely on reports of single cases rather than large groups of patients. This study will look at a large multicenter group to provide more reliable information on surgical techniques (such as open surgery vs. minimally invasive) and long-term recovery.
Who can participate in this study? The study includes patients who meet the following criteria:Adults aged 18 years or older.Patients with intrathoracic tumors measuring 5 cm or larger.Tumors that can be either benign (non-cancerous) or malignant (cancerous).Patients who underwent surgery with the intent to completely remove the tumor.The study excludes patients with common non-small cell lung cancer (NSCLC), thymomas, or sarcomas of the chest wall.
How is the study designed? This is a multicenter, retrospective and prospective cohort study. It is led by the IRCCS Azienda Ospedaliero-Universitaria di Bologna and involves six other major thoracic surgery centers in Italy (Rome, Padua, Turin, Pisa, and Milan).Researchers will review medical records of approximately 400 patients who had surgery between January 2005 and December 2024. Data will be collected on:Surgical complications during and after the operation.The type of surgical access used.Patient survival and disease recurrence.
What are the expected outcomes? Researchers hope to:Determine the rate of complications and deaths related to the surgery.Find specific risk factors (like patient health or tumor size) that lead to more complications.Compare different surgical methods to see which works best for large tumors.Measure long-term survival and how long patients stay free of disease after surgery.The results will be shared through scientific journals and international conferences to help surgeons worldwide manage these complex cases more safely.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Pietro Bertoglio, MD
- Telefonnummer: 0516478362
- E-Mail: pietro.bertoglio@aosp.bo.it
Studienorte
-
-
Bologna
-
Bologna, Bologna, Italien, 40138
- Rekrutierung
- IRCSS Azienda Ospedaliero-Universitaria di Bologna
-
Kontakt:
- Pietro Bertoglio, MD
- Telefonnummer: 0516478362
- E-Mail: pietro.bertoglio@aosp.bo.it
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
The study population consists of patients who underwent surgery for large intrathoracic tumors at the participating centers between January 2005 and December 2024. Subjects will be identified through a review of medical records, surgical registries, and outpatient documentation available at the participating facilities, and enrollment will take place during scheduled outpatient follow-up visits or via telephone contact made during postoperative follow-up, in accordance with the standard care pathway. In both cases, patient selection will be conducted in accordance with the inclusion and exclusion criteria established in the protocol, following verification of the available clinical documentation.
Beschreibung
Inclusion Criteria:
- Age ≥ 18 years
- Intrathoracic tumors ≥ 5 cm in size
- Tumors with either benign or malignant histology
- Tumors treated surgically with the aim of complete resection
Exclusion Criteria:
- NSCLC
- Thymomas
- Wall sarcomas
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: RETROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Intraoperative complication rate, postoperative complication rate
Zeitfenster: baseline
|
baseline
|
|
Relationship between the development of complications and the presence of pre- or intraoperative risk factors
Zeitfenster: baseline
|
baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Perioperative mortality rate
Zeitfenster: baseline
|
baseline
|
|
Rate of surgical approach utilization
Zeitfenster: baseline
|
baseline
|
|
Overall Survival and Disease-Free Survival
Zeitfenster: baseline
|
baseline
|
|
association of surgical approach utilization with postoperative complications
Zeitfenster: baseline
|
baseline
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- GIANTOR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .